Clinical trial NCT02735460: Usability of Andago V2.0 in Gait Rehabilitation of Stroke Patients
Official title: Single-center Usability Study of the Overground Gait and Balance Training Device Andago V2.0 in Patients With Gait Disorder After Stroke at a Center for Neurological Rehabilitation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Brain Ischemia
Intracranial Haemorrhage
Lead sponsor: Rehaklinik Zihlschlacht AG
Sponsor class: OTHER
First posted: 2016-04-12
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Andago V2.0 is a recently developed overground gait and balance training device. Many patients in neurorehabilitation suffer from gait disorders, most typically after stroke. Since pharmacological therapies are basically not available, neurorehabilitation plays an important role in the treatment of such patients. The Andago V2.0 may represent a useful device in the rehabilitation of stroke and other neurological patients featuring a severe gait disorder. Therefore a study has been designed to investigate the usability of the Andago V2.0 in the setting of a neurorehabilitation clinic. The primary outcomes of this study are the usability and acceptance of the investigational medical device (IMD). Usability is mainly measured by the time spent for the set-up and release of the participant, achieved training times and distances, the number of stumbles, collisions and emergency stops and the error messages during the session. Besides patient and therapist satisfaction with the Andago V2.0 is recorded.


Eligibility criteria: Inclusion Criteria:

* Informed consent as documented by signature
* Primary diagnosis of cerebral infarction (ICD-10: I63.0-I63.9) or intracerebral haemorrhage (ICD-10: I61.0-I69.9) independent of its location, age or cause
* Gait disorder defined by a category of 1 to 3 on the Functional Ambulation Classification (FAC) (17)
* Age above 18 years
* Admission to Rehaklinik Zihlschlacht for in-patient neurorehabilitation

Exclusion Criteria:

* Inability of the participant to understand the informed consent or to follow the procedures of the study, e.g., due to language problems, psychiatric disorders, cognitive impairment or aphasia (item 9 of the National Institute of Health Stroke Scale (NIHSS) ≥2)
* Weight \>135 kg
* Height \>200 cm
* Bone fragility (e.g., non-consolidated fractures or osteotomies including craniotomies, osteopenia, osteoporosis or symptoms or indices in the patient history that infer a higher risk of bone density reduction)
* Unstable arthroplasty
* Uncontrolled knee or ankle instability that would still pose a danger despite the Body Weight Support (BWS) (especially lateral instability)
* Lack of head control
* Joint contractures
* Relevant differences in leg length
* Skin lesions (including pressure sores or enteric stomata) in areas of contact with harness support or lower extremity loading (feet)
* Relevant sensory impairment in the lower limbs and trunk, especially with reduced pain sensation
* Recent history or significant risk of seizures
* Relevant cardiovascular conditions, e.g., cardiac insufficiency and thoracotomy, uncontrolled orthostatic hypotension or other circulatory problems, vascular disorders of the lower limbs
* Mechanical ventilation
* Long-term infusions (e.g., baclofen pump, other intrathecal pumps)
* Any medical condition preventing active rehabilitation and/or the use of the Andago V2.0 (e.g., respiratory disease, pregnancy, orthopedic conditions, infections or inflammatory disorders, osteomyelitis)
* Participation in another interventional study within the 30 days preceding and during the present study

Primary outcomes:
measure: Usability of the IMD according to the number of participants that are able to use the Andago V2.0
timeFrame: 3 weeks
measure: Acceptance of the IMD as measured by a therapist satisfaction questionnaire
timeFrame: 3 weeks
measure: Acceptance of the IMD as measured by a patient satisfaction questionnaire
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Zihlschlacht
country: Switzerland
facility: Rehaklinik Zihlschlacht, Center for Neurological Rehabilitation
Study officials:
affiliation: Rehaklinik Zihlschlacht
name: Detlef Marks
role: PRINCIPAL_INVESTIGATOR
References: